Merck successfully maintained its revenue despite significant challenges like the Singulair patent expiry, supported by strong growth in emerging markets and key product segments. Management's confident guidance for 2013 and strategic investments signal stability, likely reassuring investors in the short term. However, looming patent expirations and pipeline uncertainties may limit a substantial positive movement.

[1]